3Saraya A,Yokokura M,Gonoi T,et al.Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K+ channels[J].Eur J Pharmacol,2004,497(1):111-117.
4Maeda N,Tamagawa T,Niki I,et al.Increase in insulin release from rat pancreatic islets by quinolone antbiotics[J].Br J Pharmacol,1996,117(2):372-376.
5Gravlee GP.Endocrine,metabolic and electrolyte responses[M] // Cardiopulmonary Bypass,principles and practice.2nd ed.Baltimore:Lippincott Williams & Wilkins,2000:344-350.
6Menzies DJ,Dorsainvil PA,Cunha BA,et al.Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents[J].Am J Med,2002,113(3):232-234.
7Park-Wyllie LY,Juurlink DN,Kopp A,et al.Outpatient gatifloxacin therapy and dysglycemia in older adults[J].N Engl J Med,2006,354(13):1352-1361.
8Capparelli EV,Reed MD,Bradley JS,et al.Pharmacokinetics of gatifloxacin in infants and children[J].Antimicrob Agents Chemother,2005,49(3):1106-1112.
9Chow AA,Fowler C,Williams RR,et al.Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers[J].Antimicrob Agents Chemother,2001,45(7):2122-2125.
10Chien SC,Wong FA,Fowler CL,et al.Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers[J].Antimicrob Agents Chemother,1998,42(4):885-888.
